Nomura/Instinet analyst Christopher Marai reiterated a Reduce rating and $62.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) after the FDA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE